Dear Colleagues, 

Mesothelioma is an uncommon malignancy that was first found to be sensitive to systemic therapy of  platinum and pemetrexed in early 2000. Recently, combination of nivolumab and ipilimumab has been found to improve the outcome of mesothelioma patients over chemotherapy, particularly in those with non-epithelioid subtypes, which are known to have much poorer outcome. To further improve the outcome, it is crucial to investigate the genomic aberrations, epigenetic alterations, and changes in the immune system and tumor microenvironment.  Such knowledge will enable precision oncology and development of novel radiation techniques and systemic therapeutics for the treatment of molecular and/or immune defined subtypes of mesothelioma, which enable further improvement in survival, symptom control, and quality of life of these patients.

The goals of this Special Issue are to provide an update on the pathogenesis, molecular biology, immunology, radiological evaluation, as well as current and future potential local and systemic therapeutic approaches in mesothelioma. 

Dr. Quincy Chu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• molecular alteration
• immunology
• radiological evaluation
• radiation and systemic therapy